Loading…
← CockpitCompetitor Analysis › 688180.SS Shanghai Junshi Biosciences Co., Ltd. Class AOpen in the cockpit ↗

Shanghai Junshi Biosciences Co., Ltd. Class A688180.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese biotech developing toripalimab, a PD-1 cancer immunotherapy antibody approved in China and the US (as Loqtorzi via partner Coherus).

≈ A Chinese immuno-oncology biotech, akin to a smaller BeiGeneMomentum laggard 19
Mkt cap
$3.48B
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$46.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-7.0 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥26.63
1D+0.1%
1W-13.2%
1M-12.4%
3M-33.6%
6M-30.9%
YTD-22.0%
1Y-31.8%
ATR %4.9%
52w lowhigh42.8% off high

What Shanghai Junshi Biosciences does

Chinese biotech developing toripalimab, a PD-1 cancer immunotherapy antibody approved in China and the US (as Loqtorzi via partner Coherus).

Sells toripalimab to Chinese hospitals, where a place on the national reimbursement list opens volume at lower prices, and earns licence fees and milestone payments from partners abroad: Coherus holds the US and Canada rights under a 2021 deal. Heavy spending on trials and the antibody pipeline makes partner payments a second income stream.

In one line: A Chinese immuno-oncology biotech, akin to a smaller BeiGene.

Products and services

  • Toripalimab (PD-1 antibody)
  • Other oncology/antibody pipeline

Customers

  • Hospitals/oncologists treating cancer patients

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • PD-1/immuno-oncology antibodies

What could go right

  • Global oncology drug approvals/launches

What could go wrong

  • Clinical trial/regulatory risk
  • PD-1 market price competition

Moat: narrow (IP / patents, regulatory licence). First Chinese-developed PD-1 antibody approved in the US, protected by patents and regulatory approvals.

Headquarters: Shanghai, China · Founded: 2012 · Employees: 2,903

Named competitors

Shanghai Junshi Biosciences at a glance

Size Shanghai Junshi Biosciences (688180.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.48B, the 701st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.63 on 18 Nov 2026.

Performance Over six months the shares fell 30.9%, against +8.1% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 29.1% over the last twelve months (peer median +7.9%); the operating margin is -14.6% (peer median 12.2%).

Valuation It trades at 8.1× enterprise value to sales against a peer median of 3.1× (4th most expensive of 16).

Capital Return on invested capital runs 7.0 points below its cost of capital (5.0% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 111688180.SS 71
Six months, rebased to 100: Shanghai Junshi Biosciences against the median of its 20 peers (local-currency closes).

Shanghai Junshi Biosciences financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.21BCN¥2.49BCN¥1.94BCN¥1.50BCN¥1.45B
Revenue growth—+28%+30%+3%—
Gross profitCN¥2.75BCN¥1.81BCN¥1.31BCN¥714MCN¥718M
EBITDAn/a-CN¥615M-CN¥1.01B-CN¥2.18B-CN¥2.45B
Net income-CN¥429M-CN¥875M-CN¥1.28B-CN¥2.28B-CN¥2.39B
Free cash flow-CN¥748M-CN¥1.25B-CN¥2.07B-CN¥2.73B-CN¥2.11B
Capital expenditureCN¥787MCN¥768MCN¥691MCN¥833MCN¥394M
Total debtCN¥6.82BCN¥4.14BCN¥2.93BCN¥1.79BCN¥1.32B

Quarterly statements and history in the cockpit →

Shanghai Junshi Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%+40%002262ARQTACUTAASSFZNWOCKPHARMAAMLXVRDN2096PPLPHARMA000739600521OGNSLSXENE1513TARS688180.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Junshi Biosciences is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×002262ARQTACUTAASSFZNWOCKPHARMAVRDN2096000739TARS688180.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Junshi Biosciences is the large dot.

Shanghai Junshi Biosciences competitors and peer comparison

Head to head with its named competitors (688180.SS vs 688235.SS vs 1801.HK vs MRK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Shanghai Junshi Biosciences 688180.SS$3.48B-31%+29%-15%8.1×n/a
BeOne Medicines 688235.SS$45.5B+9%+25%18%6.3×19.1%
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%
Merck & MRK$340B+23%+5%18%5.7×8.3%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%8.0×13.4%
Akeso 9926.HK$7.01B-48%+42%-25%12.9×n/a
Shanghai Henlius Biotech 2696.HK$3.05B-39%+33%12%3.3×14.1%
CStone Pharmaceuticals 2616.HK$1.21B-22%+117%-89%17.0×n/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%

How Shanghai Junshi Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Junshi Biosciences against its 20 peers (data as of 18 Nov 2026)
Measure688180.SSPeer medianRank in peer set
1-month return-12.4%+4.5%2nd lowest of 21
6-month return-30.9%+8.1%2nd lowest of 20
Distance from 52-week high-42.8%-18.8%2nd lowest of 21
Revenue growth (TTM)+29.1%+7.9%5th highest of 18
Operating margin-14.6%12.2%2nd lowest of 16
EV / Sales8.1×3.1×4th most expensive of 16
ROIC minus cost of capital-7.0 pp+4.3 pp5th lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%8.1×n/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%3.1×-2.1%+12.0%
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%6.6×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%20.4×n/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%2.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%106.6×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%2.6×-3.4%+10.6%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%3.8×n/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%2.5×4.7%+4.5%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%1.8×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
China National Medicines 600511.SSChina$3.26B+3%+3%4%0.3×-10.0%+5.4%
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%2.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%5.2×34.7%+159.5%

Questions

Who are Shanghai Junshi Biosciences's main competitors?
Named competitors: BeiGene (688235.SS), Innovent Biologics (1801.HK), Merck (MRK), Jiangsu Hengrui Pharmaceuticals (600276.SS), Akeso (9926.HK), Shanghai Henlius Biotech (2696.HK). The cockpit's measured peer set (industry) also includes Jiangsu Nhwa Pharmaceutical (002262.SZ), Arcutis Biotherapeutics (ARQT), Acutaas Chemicals (ACUTAAS.NS), Siegfried (SFZN.SW), Parabilis Medicines (PBLS), Wockhardt (WOCKPHARMA.NS).
Is Shanghai Junshi Biosciences expensive compared with its peers?
On ev / sales it trades at 8.1× against a peer median of 3.1×, 4th most expensive of 16 in its peer set.
How has Shanghai Junshi Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -30.9% against +8.1% for the median peer; over one year -31.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.